MedTrace Logo

HP184 in Chronic Spinal Cord Injury Subjects

NCT00093275 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 262

Last updated 2008-08-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether HP184 is effective in the treatment of chronic spinal cord injury (CSCI).

Conditions

  • Spinal Cord Injury

Interventions

DRUG

HP184

Sponsors & Collaborators

Principal Investigators

  • ICD CSD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States
  • Australia
  • Germany
  • India
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00093275 on ClinicalTrials.gov